Valuation: Azitra, Inc.

Market Cap 8M 7.14M 6.65M 6.05M 11.39M 770M 11.48M 80.34M 31.26M 393M 30.03M 29.38M 1.26B P/E 2026 *
-0.66x
P/E 2027 * -1.39x
Enterprise Value 8M 7.14M 6.65M 6.05M 11.39M 770M 11.48M 80.34M 31.26M 393M 30.03M 29.38M 1.26B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.41%
Yield 2026 *
-
Yield 2027 * -
1 day+1.52%
1 week-22.12%
Current month-4.07%
1 month-23.26%
3 months-11.23%
6 months-42.86%
Current year-50.15%
1 week 0.12
Extreme 0.1231
0.17
1 month 0.12
Extreme 0.1231
0.19
Current year 0.1
Extreme 0.1
0.38
1 year 0.1
Extreme 0.1
1.09
3 years 0.1
Extreme 0.1
455.54
5 years 0.1
Extreme 0.1
1,034.97
10 years 0.1
Extreme 0.1
1,034.97
Manager TitleAgeSince
Chief Executive Officer 56 2021-03-31
Chief Operating Officer 36 2023-05-31
Director of Finance/CFO 56 2022-09-30
Director TitleAgeSince
Director/Board Member 36 2014-01-01
Director/Board Member 56 2021-03-31
Director/Board Member 66 2023-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/20/26 Free

Founder

64,300 0.3971%
4/20/26 Free

Chief Executive Officer

220,879 1.3641%
4/20/26 Free

Chief Financial Officer

35,524 0.2194%
Change 5-day change 1-year change 3-year change Capi.($)
+1.52%-22.12%-83.14%-99.96% 8M
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.81%+19.51%+78.12% 57.39B
+1.63%-1.61%+3.16%+36.89% 47.64B
-0.52%+1.43%+339.31%+710.10% 44.29B
+1.68%-2.94%+28.28%+32.95% 42.5B
+0.60%-1.94%+4.46%+110.87% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.34%-2.13%-7.79%-11.73% 24.34B
Average +0.98%-2.66%+39.38%+103.24% 39.05B
Weighted average by Cap. +1.18%-0.84%+57.19%+135.06%

Financials

2026 *2027 *
Net sales - -
Net income -12.45M -11.11M -10.35M -9.42M -17.74M -1.2B -17.87M -125M -48.66M -612M -46.75M -45.74M -1.97B -16.88M -15.05M -14.03M -12.76M -24.04M -1.63B -24.21M -169M -65.94M -829M -63.35M -61.98M -2.67B
Net Debt - -
Logo Azitra, Inc.
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live bio therapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, chronic, xerotic (abnormally dry), and scaly skin disease.
Employees
-
Date Price Change Volume
26-10-05 US$0.1320 0.00% 285,725
26-10-02 US$0.1320 +2.72% 825,843
26-10-01 US$0.1285 -6.61% 1,429,203
26-09-30 US$0.1376 +5.36% 611,017
26-09-29 US$0.1306 -22.95% 3,214,474
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1320USD
Average target price
0.6700USD
Spread / Average Target
+407.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AZTR Stock